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Abstract 
 Unnatural amino acids (UAAs) permit the incorporation of novel biochemical 
functionalities into proteins. This expansion of the genetic code has enabled enhanced 
spatial and temporal control of protein activity and conferred novel protein reactivity. 
This study examines the incorporation of three UAAs: fluoro-tyrosine, ortho-nitrobenzyl-
tyrosine, and propargyloxy-phenylalanine towards various applications. Each UAA was 
successfully incorporated into a protein of interest (GFP or PRMT1) to facilitate the 
desired manipulation of protein function. The resulting alterations to GFP fluorescence, 
PRMT1 activity, or immobilization using Glaser-Hay bioconjugation demonstrate the 
success and practicality of the utilization of UAAs in the development of novel 
biochemical tools.  
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I. Introduction to Unnatural Amino Acids 
A. What are Unnatural Amino Acids (UAAs) 
As apparent by the wide amount of diversity within living things, the twenty amino 
acids that compose all proteins are quite functional and adaptable due to their diverse 
range of biochemical functions. Proteins are the main machinery of a cell and provide 
cell structure, regulation of cell activities, and the overall catalysis of processes vital to 
cells.
1
 Regulation of a cell’s activities occurs through the regulation of protein 
concentration and protein activity. The genetic code, contained within DNA, consists of 
trinucleotide sequences called codons that encode one amino acid. As there are 64 
possible codons from the four different nucleotides (4
3
), there exists a certain amount of 
degeneracy in the code for amino acid incorporation. Regulation of transcription (the 
formation of mRNA from DNA) or translation (the formation of protein from mRNA) 
determines the amount of protein in the cell. Once protein is made from the twenty 
available amino acids, a number of post-translational modifications can occur. These 
modifications involve the additions of functional groups to the protein structure such as 
phosphorylation, methylation, acetylation, and glycosylation, which broaden the range of 
applications of proteins. However, despite these additions, the chemical composition of 
proteins is rather limited as the canonical twenty amino acids contain no alkynes, azides, 
halogens, etc. (Figure 1.1).
2
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Figure 1.1: The structure of the canonical twenty amino acids. Each amino acid has a 
carboxylic and an amino functionality that allows them to be joined together in peptide 
bonds to form proteins. Each amino acid contains a slightly different R group that can be 
altered to produce UAAs.  
To address these limitations, “unnatural” amino acids (UAAs) that contain novel 
functionalities can be synthesized.  Some naturally occurring UAAs exist, such as the 21
st
 
and 22
nd
 amino acids, selenocysteine and pyrrolysine, which are found in several bacteria 
and archaea.
3–5
 Selenocysteine is modified with selenium instead of sulfur on a cysteine 
and pyrrolysine has a pyrroline ring on a lysine (Figure 1.2). The possibilities for the 
unnatural amino acids are only limited by our knowledge of chemistry, our synthetic 
capabilities, and our ability to incorporate the UAA into protein (due to constraints 
imposed by recognition of the UAA (e.g. size limits)).  
 
 
3 
 
 
The amino acid modifications translate to structure and function alterations of the 
protein of interest. Addition of specific elements (such as metals, fluorine, reactive 
chemical functionalities, etc.) can be used for x-ray crystallography, fluorescent probes, 
or for reactive chemistry such as click reactions (Figure 1.3).
4
 The development of UAA 
technologies is not only a quest for an expanded genetic library, but also a useful tool in 
therapeutics, engineering, and agriculture (fungicides) among other fields.
2,6
 The 
manipulability of the UAAs allows for specificity that cannot be obtained when confined 
to using the original twenty amino acids. 
This paper will explore the synthesis, incorporation into proteins, and applications of 
three unnatural amino acids: fluoro-tyrosine, ortho-nitrobenzyl-tyrosine, and 
propargyloxy-phenylalanine (Figure 1.4). As the range and utility of UAAa is a vast and 
expanding field, this paper presents only a small sampling of all that can be done with an 
expanded amino acid library. 
 
Figure 1.2: The structures of selenocysteine (Sec) and pyrrolysine (Pyl).  
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Figure 1.3: Examples of currently incorporated UAAs.  
 
Figure 1.4: The structures 3-fluoro-tyrosine, ortho-nitrobenzyl-tyrosine, and 
propargyloxy-phenylalanine 
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B. UAA Protein Incorporation 
There are a number of methods that can be used to incorporate the UAAs into 
proteins, each with their own advantages and drawbacks. New methods are continually 
being developed to perfect the speed and applications of the protein synthesis. Early 
methods began on a purely chemical basis (solid-phase synthesis), yet newer methods 
utilize cellular mechanisms in E. coli, yeast, and mammalian cells, to express proteins 
containing UAAs in vivo. This section focuses exclusively on the incorporation of the 
UAA into protein. The synthesis itself of the UAA is commonly done via common 
organic synthesis in the laboratory, and will thus not be covered. 
B.1 Solid Phase Protein Synthesis (SPPS)  
 Solid Phase Protein Synthesis (SPPS) is primarily a chemical approach to the total 
synthesis of a protein. Each amino acid is individually linked onto the growing peptide 
chain like placing beads on a chain. A resin serves as the solid base/protecting group for 
the amino acids to attach to a linker which can easily be cleaved off at the end of peptide 
synthesis. To eliminate cross-reactions, the employed amino acids are modified with 
protecting groups like tert-butyloxycarbony (BOC) or fluorenylmethyloxycarbonyl 
(FMOC) groups which can easily be cleaved using a weak base or acid once the amino 
acid is attached to the chain.
7
 The general process of SPPS is a cycle of  deprotections, 
washes and couplings until the peptide chain is complete (Figure 1.5).
7
 Once the 
polypeptide chain is complete, it can be cleaved off the resin and then purified. The 
duration of this process (purification included) varies with the length of the desired 
peptide: a peptide under ten amino acids takes approximately a day, while a forty amino 
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acid peptide takes a week (~80 hours).
8
 Peptide synthesizers are also available to use, and 
give comparable yield to those synthesized by hand.  
 
 SPPS has been used to commercially produce small polypeptides such as insulin-
like growth factors and human immunodeficiency virus 1 (HIV-1) protease which can 
then be used to determine the crystal structure of these proteins.
9
 Due to the bottoms-up 
approach of this synthesis, UAAs can easily be added in either as a single unit of the 
chain, or as an entire synthetic strand. However, the major flaw of this method is the 
 
Figure 1.5: Overall scheme of SPPS.7  
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length of the peptide that can be produced is limited to under 50-100 amino acids due to 
poor yields at increased length resulting from protein aggregation.
10
 As many proteins 
extend beyond 100 amino acids (the largest protein Titin is 3–3.7 MDa), this method is 
not adequate to construct all proteins of interest.
11
 
B.2 Global Incorporation 
 For larger proteins than what can be synthesized through SPPS, global 
incorporation of UAAs is a viable option. Global incorporation of a UAA involves the 
replacement of the canonical amino acid analog with UAAs throughout the protein of 
interest. This is done through starving the E. coli of the amino acid that most resembles 
the desired unnatural, while providing the desired amino acid analog (such as tyrosine for 
a fluorotyrosine incorporation).
12
 This accomplishes a global incorporation of the UAA in 
multiple positions in the protein. As the van der Waals radius of fluorine is only 0.15Å 
larger than hydrogen, this is easily done for fluorinated analogues.
12
 A case where 
multiple additions are favorable is 
19
F NMR which has high sensitivity with minimal 
background signal.
2
 However, global incorporation is not conducive to exponential cell 
growth as often times the analog is toxic to cells.
3,9
 An additional disadvantage is that this 
method does not afford site-specific incorporation (in which the UAA is added at specific 
locations in the protein). Site-specific incorporation is important in precise adjustment of 
protein function, such as modifications made to the active site that would otherwise not 
be possible with global incorporation. 
B.3 Orthogonal Aminoacyl tRNA Synthetases (aaRS) 
Transcription is the biological process that transcribes DNA (the genetic material 
which encodes the information for proteins) to mRNA (the messenger material of this 
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code). The mRNA is then translated into protein through a process known as translation. 
Each set of three nucleotides (called a codon) encodes a specific amino acid. The tRNA 
contains an anti-codon and delivers the associated amino acid to the ribosome where it is 
attached to the growing polypeptide chain. The tRNA is charged with the respective 
amino acids by an aminoacylation catalyzed by aminoacyl-tRNA synthetases (aaRS) 
(Figure 1.6).  
 
 
Figure 1.6: Normal translation with a canonical aaRS/tRNA pair is shown on the left 
where the tRNA is charged by the coordinate aaRS with the appropriate amino acid. 
The anticodon of the tRNA base-pairs with the codon to allow the insertion of the 
amino acid into the growing polypeptide chain.  On the right, the orthogonal 
aaRS/tRNA pair responds to the mutated codon to allow site-specific insertion of the 
UAA.3 
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Translation provides the main mechanism for site-specific UAA insertion into 
proteins through the modification of the aaRS and tRNA.
9,13
 As the UAAs do not 
naturally have a tRNA that correlates for a codon, or an aaRS to attach it to the tRNA, a 
method of introducing these translational tools must be accomplished. There are three 
stop codons which do not have a specific tRNA, but rather encode a translational stop. 
One of these is the amber nonsense codon which is encoded by the trinucleotide sequence 
UAG. This codon can be re-purposed to incorporate UAAs in response to its presence in 
the mRNA transcript. One method to incorporate a UAA is to utilize chemically pre-
aminoacylated tRNAs that recognize the UAG codon; however this mechanism is not a 
sustainable system  due to low yields, difficult purification, and continual need for pre-
charged tRNAs during protein synthesis.
14
  
An orthogonal aaRS that can attach UAAs to the suppressor tRNA is desirable 
and more common approach to UAA incorporation. Orthogonal refers to the fact that the 
new aaRS does not cross-react with any of the other endogenous tRNAs and the tRNA 
does not react with any endogenous aaRSs.
9
 An orthogonal aaRS and suppressor tRNA 
can be derived from phylogenetically different organisms from the host (like the archaea 
Methanocaldococcus jannaschii) to recognize this codon and the UAA of interest, while 
not recognizing any of the endogenous set.
3
 The development of the aaRS/tRNA pair is 
accomplished via directed evolution utilizing two phases of selection: (1) positive 
selection to select mutants that incorporate any amino acid, and (2) negative selections to 
select against mutants that incorporate endogenous host amino acids (Figure 1.7).
3
 For 
this process in each phase, a library of aaRS mutants is transformed into E. coli with the 
orthogonal tRNA with a TAG mutation in a selected gene. For the positive selection, the 
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gene containing the TAG encodes chloramphenicol resistance, such that when the cells 
are grown on a plate containing chloramphenicol and the UAA of interest, only those that 
have successfully suppressed the amber codon through insertion of the UAA will be able 
to survive. These colonies are then picked and the successful aaRS plasmids are subjected 
to the negative step as the colonies could have incorporated a canonical amino acid to 
survive. In the negative selection, the selection plasmid contains stop codons in a gene for 
barnase, a bacterial toxin, and the cells are grown without the UAA. If the amber codon is 
now suppressed, through incorporation of a canonical amino acid, the cell will die, 
whereas if they only recognize the UAA they do not produce barnase since no UAA is 
present in the selection. This selection process goes for 2.5 rounds and ultimately ends on 
a positive step to provide an aaRS/tRNA pair capable of incorporating the UAA. 
 
 
Figure 1.7:  The selection process of the MjaaRS/MjtRNA pair (derived from M. 
jannaschii) to develop a aaRS that will recognize the UAA of interest. This cycle of 
selection will be completed 2.5 times, ultimately ending on a positive step, to develop 
a orthogonal synthetase for the UAA.  
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In this way, wherever the amber codon is present it is suppressed and the UAA 
will be inserted in its place. This also presents a mechanism for quality control, as the 
proteins that do not successfully incorporate the UAA will terminate in response to the 
stop codon. This implies that proteins that do not have the UAA will be significantly 
shorter and lack the functionality of the wild type protein, providing an opportunity for 
purification techniques to select only the proteins with the UAA correctly inserted if the 
terminated peptide was not naturally degraded. 
The overall method of using nonsense codons is as follows: (1) mutation of the 
point of interest in DNA to a nonsense/stop codon; (2) isolation of a tRNA that 
recognizes the nonsense codon;  and (3) selection aaRS that can attach the tRNA with the 
desired UAA.
5
 While typically each UAA requires its unique aaRS, an advantageous 
aspect that can develop in the selection of the orthogonal aaRS is polyspecificity. 
Polyspecificity is the ability to recognize multiple UAAs, which results from the absence 
of selective pressure for other UAAs than the one employed in the selection.
15
 The 
development of these promiscuous synthetases is critical to the continued use and 
development of this technology. One such example is p-cyanophenylalanine specific 
aminoacyl-tRNA synthetase (pCNF-RS) which is able to successfully incorporate 18 
UAAs into protein.
15
  This polyspecificity is developed coincidentally in the aaRS 
selection process through the use of one UAAS similar in structure to many others. 
Additionally, incorrect selection can produce a polyspecific synthetase through a 
decreased number of selection rounds. This leads to more flexibility in the recognition of 
UAAs by the aaRS, proving desirable synthetase polyspecifity for attaching more than 
one UAA to the tRNA.  
 
 
12 
 
Through the use of a cell’s own translational machinery, polyspecific orthogonal 
aaRS and its cognate suppressor tRNA are able to selectively insert a number of UAAs 
into the protein of interest for future study.
3
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II. Fluorescent Biosensors: Fluorotyrosines 
A. Introduction to Fluorescent Biosensors 
 Fluorescent proteins occur naturally and can be utilized as biomarkers/biosensors 
to monitor cell activity in real-time through the interactions of the analyte of interest with 
the fluorescent protein.
16,17
 The addition of UAAs allow an opportunity for enhanced 
specificity and efficiency of these fluorescent biosensors in comparison with the wild 
type. The chemical/physical property of the UAA is selected to generate a fluorescence 
change (activation or quenching) upon contact of the analyte. Fluorescent protein 
biosensors have been used to study intercellular pH, redox potentials, protein-protein 
interactions, concentrations of specific small molecules (like metals), and enzyme 
activity.
16
 For example, an unnatural fluorescence biosensor was used to observe the 
phosphorylation of Crk-II (an overexpressed protein in cancer cells).
18
 
There are three possible designs of a natural fluorescent protein biosensor to 
which a UAA can be incorporated: (1) multiple fluorescent proteins are linked by a 
scaffold such that once a stimuli is sensed, there is a conformational change so that the 
distance between the two fluorescent proteins is altered to result in a shift in fluorescence 
resonance energy transfer (FRET); (2) the fluorescent protein with its associated sensing 
domain is split into two but in the presence of the analyte the two come back together to 
the fused native structure and fluorescence; (3) a single fluorescent protein undergoes a 
conformational change as the sensing domain recognizes the analyte which leads to shift 
in fluorescence intensity or hue (Figure 2.1).
16
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Green fluorescent protein (GFP) is a natural fluorescent protein that was found in 
deep sea jellyfish, Aequorea victoria. Its structure is a β-barrel surrounding an α-helix 
that contains the fluorophore responsible for GFP’s fluorescence (Figure 2.2). GFP’s 
fluorescence is determined by the fluorophore which is composed of a serine, dehydro-
tyrosine and glycine at residues 65-67 that have cyclized to form an imidazolidone ring 
(Figure 2.3).
19
 Gly67 is highly conserved in all fluorescent GFP mutants as it functions as 
 
Figure 2.1: Possible designs of fluorescent biosensors. A) FRET biosensor B) 
bimolecular complementation biosensor C) single fluorescent protein and D) Single 
fluorescent protein with UAA.16  
 
 
15 
 
an important nucleophile with limited steric hindrance for the cyclization.
20
 The 
fluorescence of GFP has been well characterized, which makes it a useful fluorescent 
probe. 
 
 
Figure 2.2: The structure of GFP is a β-barrel with an inner α-helix. The positions 
labeled are tyrosine residues of interest for UAA incorporation. Y66 is in the 
fluorophore while Y151 is on the rigid β-barrel 
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Due to the importance of the tyrosine phenol in the fluorophore, changes in 
protonation states result in two separate exited states of GFP. The protonated tyrosine is 
excited at 395 nm (emission at 512 nm) while the deprotonated state results in excitation 
at 475 nm (emission at 503 nm) (Figure 2.4).
19,20
 A proposed mechanism for this switch 
between the protonation states of the buried fluorophore involves proton transfer using 
the hydrogen bonds of a buried water molecule and Ser205 to Glu222 while Thr203 
stabilizes the phenolate oxyanion (Figure 2.5).
20
 In a non-irradiated state, wild-type GFP 
exists in a 6:1 ratio of the neutral-to-anionic states, however this ratio shifts in favor of 
the anionic states after excitation due to the phenol becoming more acidic in its excited 
 
Figure 2.3: The formation of the fluorophore from the tripeptide region of GFP (Ser65, 
Tyr66, Gly67).  The cyclization follows a series of steps including the initial folding 
and cyclization, enolization, and the dehydration and oxidation that finally results in 
the functional fluorophore.20  
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state.
20
 Because of this dependence on protonation of the phenol for excitation, GFP 
naturally displays pH sensitivity that could be modified for an enhanced range of 
sensitivity. 
 
 
 
Figure 2.4: The excitation (solid line) and emission (dashed) of the two protonation 
states of GFP fluorophore.20   
 
Figure 2.5: The chromophore and its environment in GFP.19  
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GFP is very commonly used as a modified fluorescent protein once it has been site-
specifically engineered with UAAs. For a system to be biologically useful as a probe it is 
desirable that it contain the following characteristics: (1) specific to analyte, (2) display 
signal enhancement upon activation, (3) be orthogonal to cellular events, and (4) be 
genetically encoded by cells of interest.
16
 All of these characteristics can easily be 
obtained using UAAs and GFP to study specific cellular effects with a noticeable visual 
correlation. This study seeks to determine the alteration in pH sensitivity of GFP as a 
result of UAA incorporation at multiple residues, including Y66 in the fluorophore.  
 
B. UAA: Fluorotyrosines  
The amino acid tyrosine (Y) is polar and contains a phenol ring. Fluorotyrosine is 
obtained through the addition of fluorine at one or multiple of the four possible positions 
on the phenol ring (Figure 2.6). The fluorine substitution is considered to be isosteric in 
that it does not perturb the spatial environment that it is placed in; however, it does have a 
very high electronegativity.
12
 This electronegativity has the potential to alter the pKa of 
the tyrosine phenol which can be useful in biological probes.  
 
Figure 2.6: The structure of the six fluorotyrosine variants that were studied. (1) 2,3,5-
F
3
Y ; (2) 3-F
1
Y; (3) 2,3-F
2
Y; (4) 3,5-F
2
Y; (5) 2,3,6-F
3
Y; (6) 2,3,5,6-F
4
Y. 
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The UAA 3-fluorotyrosine (2) has been used as a method to determine the structure 
and kinetics of proteins such as hemoglobin
21
, organophosphate hydrolase
22
 or human 
manganese superoxide dismutase
23
. Due to the electronic properties of the fluorine, it can 
also be used to study electron transport systems such as in photosystem II.
24
 The ability 
for amino acids like tyrosine to form radicals is especially important in biological 
catalysis; fluorotyrosines provide a mechanism of studying the reactivity of tyrosine 
radicals.
25
  
Fluorotyrosine may find application in biological probes such as GFP. As discussed 
previously, the tyrosine at position 66 is an important determinant in the fluorescence of 
the protein. Through the addition of a single fluorotyrosine residue into GFP at Tyr66, we 
may be able to alter the properties of the chromophore to change the protein function.
12
 
We hypothesize that the greater the number of fluorines that are added to Tyr66, the 
greater the electronegativity, and the greater the acidity, of the tyrosine phenol which will 
change the spectrophysical characteristics of the GFP. The changes in protonation state of 
tyrosine changes the chromophore which will allow it to be used as a pH sensor. The 
addition of fluorine to tyrosine changes the  pKa from the typical 10 of a tyrosine to 9.0-
5.2 (depending on the number of fluorine additions) (Table 2.1).
12
 This study explores the 
incorporation of a variety of fluorotyrosine into GFP to study this process.
26
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C. Methods  
General 
Solvents and reagents were obtained from either Sigma-Aldrich or Fisher Scientific and 
used without further purification. All GFP proteins were purified according to 
manufacturer’s protocols using a Qiagen Ni-NTA Quik Spin Kit. Fluorescence was 
analyzed using a Perkin Elmer LS 55 Luminescence Spectrometer at excitations 300 nm, 
320 nm, and 395 nm. Fluorotyrosines were custom ordered from a commercial source. 
Expression of GFP-Fluorotyrosines 
Escherichia coli BL21(DE3) cells were co-transformed with a pET-GFP-TAG-66 or 
pET-sfGFP-TAG-151 plasmid (0.5 μL) and pEVOL-3FY plasmid (0.5 μL) using an 
Eppendorf electroporator. Cells were then plated on LB-agar plates supplemented with 
ampicillin (50 mg/mL) and chloramphenicol (34 mg/mL) and grown at 37°C. After 16 h, 
a single colony was selected and used to inoculate LB media (4 mL) supplemented with 
ampicillin and chloramphenicol. The culture was grown at 37°C for 12 h. The culture 
was used to begin an expression culture of LB media (10 mL) at OD600 0.1, then 
incubated at 37°C, to an OD600 of ~0.6, at which point cells were induced with 1 M IPTG 
(10 μL), 20% arabinose (10 μL) and 100 mM (100 μL) of respective fluorotyrosine (3FY; 
Tyrosine Derivative pKa 
Y 10 
3-F
1
Y 8.4 
3,5-F
2
Y 6.8 
2,3-F
2
Y 7.6 
2,3,5-F
3
Y 6.1 
2,3,6-F
3
Y 6.6 
2,3,5,6-F
4
Y 5.2 
 
Table 2.1: The pKa of each fluorotyrosine derivative. 
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2,3F2Y; 3,5F2Y; 2,3,5F3Y; 2,3,6F3Y). Cultures were grown for an additional 16 h at 
37°C, then harvested by centrifugation (10 min at 10,000 rpm). The media was decanted 
and the cell pellet placed in the -80°C freezer for at 20 min. Purification was 
accomplished using commercially available Ni-NTA spin columns and according to 
manufacturer’s protocol. Protein yield and purity was assessed by SDS-PAGE, and 
spectrophotometrically using a Nanodrop spectrophotometer. 
Measurement of Fluorescence 
Samples for fluorescence of both GFP-TAG-66 mutants and sfGFP-TAG-151 
(concentration ~0.2-0.5 mg/mL) were prepared by a 1:300 dilution in PBS buffer or 1X 
Tris Buffer. Sample fluorescence was measured using a Perkin Elmer LS 55 
Luminescence Spectrometer. Excitation was at 395nm with excitation and emission slit 
widths of 10 nm. Emission was recorded between 410 nm and 600 nm.  Peak shifts were 
recorded for each fluorotyrosine variant. To explore the changes in pH sensitivity, 
aliquots of 2 μL 1M NaOH or 0.6M HCl were added. Acid was added if the intensity of 
the 512 nm peak was larger than the 450 nm peak (and the reverse for adding base). 
Qualitative observations of the fluorescence shifts were made after graphing emission 
peaks for each variant.  
To more quantitatively determine the pH sensitivity, samples were given to the Harbron 
lab to analyze with a Varian Cary Eclipse Fluorescence Spectrophotometer. Samples 
were prepared by a 1:100 dilution with PBS buffer or 1X Tris Buffer with aliquots of 1M 
NaOH or 0.6M HCl. At each increment, the pH was measured using a Mettler Toledo 
microelectrode pH probe. Data analysis to test for titration curves was done using IGOR 
software program. 
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Synthesis of 2,3,5,6 F4Y-A 
The tetra-substituted fluorotyrosine (2,3,5,6 F4Y (6)) was unable to be taken up by the 
cell and incorporated into GFP. To increase its uptake, the synthesis of a dipeptide of 6 
and alanine was attempted. Initial trials to make the dipeptide were unsuccessful, so the 
reaction conditions were attempted with the synthesis of Tyr-Ala. Two set of dipeptide 
coupling conditions were attempted. One utilized the coupling agent N,N'-
dicyclohexylcarbodiimide (DCC) (58.7 mgs, 0.8 eq, 0.285 mmol), however these 
conditions resulted in no recoverable product. A different coupling agent, 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI), was then attempted for subsequent reactions.  
To be able to react with the free carboxylic end of tyrosine, the carboxylic end of  Boc-
Ala-OH (0.25 g, 1eq, 1.32 mmol) was first methylated using NaHCO3 (0.33 g, 3eq, 3.96 
mmol) and CH3I (0.071 mL, 1.1eq, 1.45 mmol) in 4 mL  dimethylformamide (DMF). The 
reaction was stirred at 60ºC for 4 days (Scheme 2.1). The reaction was then extracted into 
ethyl acetate and water. Column chromatography was performed with 1:3 (hexanes: ethyl 
acetate) for 10 fractions, then 1:1 for 15 more fractions. The isolated Boc-Ala-Me was 
then reacted with 1% trifluoroacetic acid (1 mL) on ice for 5 min followed by stirring at 
room temperature for 1 hr to cleave the Boc protecting group (Scheme 2.1).  
 
The tyrosine to react with NH2-Ala-Me was obtained commercially and the methyl 
protecting group of Boc-Tyr-Me was cleaved with 1 M LiOH (0.5 mL) and 1M dioxane 
Scheme 2.1 
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(0.5 mL) on ice for 5 min before stirring for 1 hr at room temperature (Scheme 2.2). 1M 
HCl was added dropwise until the solution reached a pH of 4. Boc-Tyr-OH was extracted 
with ethyl acetate in a vial, and the organic extracted was dried with MgSO4 and 
concentrated. 
 
The dipeptide coupling was done between NH2-Ala-Me (0.013 g, 1 eq, 0.126 mmol) and 
Boc-Tyr-OH (0.035 g, 1 eq, 0.126 mmol) in a vial with hydroxybenzotriazole (HOBt) 
(0.017 g, 1 eq, 0.126 mmol) in 2 mL of 5% DMF/DCM and trimethylamine (TEA) 
(0.0176 mL, 1 eq, 0.126 mmol). Carefully EDCI (0.026 g, 1.05 eq, 0.132 mmol) was 
added into vial and the reaction was stirred overnight at room temperature (Scheme 2.3). 
The product was extracted with DCM and a column was run using 3:1 (hexanes: ethyl 
acetate) for 20 fractions and 1:1 for 10 fractions. 7 mg of product was obtained in a yield 
of 15%. 
 
Scheme 2.2 
 
Scheme 2.3 
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Using the procedure from above, more Boc-Ala-OH was methylated to react with the 
tetra-fluorinated tyrosine (Fmoc-4FTyr-OH (6)). Similar to the synthesis of Tyr-Ala 
dipeptide, 6 (0.02 g, 1 eq, 0.0603 mmol) and NH2-Ala-Me (0.0124 g, 2 eq, 0.121 mmol) 
were added to a vial with HOBt (0.0081 g, 1 eq, 0.0603 mmol) and TEA (0.0084 mL, 1 
eq, 0.0603 mmol) in 5% DMF/DCM. EDCI (0.0178 g, 1.05 eq, 0.0905 mmol) was added 
carefully to the vial which was stirred for two days at room temperature (Scheme 2.4). 
The product was extracted into DCM and brine. Column chromatography with 1:1 
(hexanes: ethyl acetate) for 25 fractions and ethyl acetate for the final 5 fractions yielded 
product. A methanol flush was done after the column was performed to ensure that the 
product did not remain on the column. NMR data revealed residual starting material so an 
extraction in ethyl acetate was performed.  
Deprotection of the Fmoc group was done using 10% piperidine/DCM (2 mL) for at least 
12 hr, followed by a pipette column to remove the cleaved Fmoc-group (Scheme 2.4).  
1% TEA was added to the column in addition to 1:3 (hexanes: ethyl acetate) for 13 
fractions, followed by 1:5 for 10 fractions and 1:7 for an additional 5 fractions before a 
final methanol flush of the column. Final deprotection of the product was done as 
previously described to remove the methyl group; however, the product was in the water 
layer so product was concentrated rather than extracted (Scheme 2.4). 4 mgs of product 
was obtained in a 20% yield. The product was used later in expressions of pET-GFP-
TAG66/pEvol-3FY, however protein purification did not yield successfully incorporated 
tetra-fluorotyrosine-alanine. 
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D. Results  
To incorporate GFP with fluorotyrosine, E. coli cells were first transformed with 
pEVOL-3FY and either pET-GFP-TAG66 or pET-sfGFP-TAG151 plasmids to afford 
site-specific incorporation of fluorotyrosine at the two positions on GFP (Y66 in the 
fluorophore and Y151 on the rigid β-barrel). Superfolder GFP (sfGFP) is a GFP variant 
with optimized fluorescent properties (such as increased fluorescence intensity and 
robustness).
27
 Five different fluorotyrosine UAAs (1-5) were incorporated into each of 
the positions of GFP to study. A tetra-substituted fluorotyrosine (6) also was attempted, 
however it was found to be too cell impermeable to be taken up by the cells and 
incorporated into protein. To attempt to resolve this, a dipeptide with alanine was 
unsuccessfully attempted. Future studies include the synthesis and analysis of this 
fluorotyrosine-alanine variant.  
With the GFP-FY mutants in hand, fluorescence was measured to observe the 
relationship between the fluorotyrosine derivative and the spectral shifts on the GFP 
Scheme 2.4 
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fluorophore. Preliminary results using Perkin Elmer LS 55 Luminescence Spectrometer 
demonstrated unique spectra for each GFP-FY mutant with incorporation of 
fluorotyrosine at both positions Y66 and Y151. For each GFP-FY variant, fluorescence 
was measured at excitation wavelengths 300 nm, 320 nm, and 395 nm as determined by 
initial analysis based on the results of an excitation scan on the GFP. As the degree of 
spectral alteration from incorporation of the fluorotyrosines into GFP was unknown, 
these additional peaks were chosen. Additionally, higher excitations were not examined 
due to the possible interference of excitation with the emission of GFP-WT, which would 
make comparison challenging.  
For the GFP-TAG66-FY mutants, the varying number of fluorines attached to the 
tyrosine shifted the 512 nm emission peak at all excitation wavelengths (Figures 2.7-2.9 
and Table 2.2). The relationship between the incorporation of fluorotyrosines in the 
fluorophore, and the resulting shift in the emission peaks remains to be elucidated.  
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Figure 2.7: Emission spectra of GFP-TAG66-FY incorporated with each fluorotyrosine 
variant. Protein was excited at 300 nm. 
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Figure 2.8: Emission spectra of GFP-TAG66-FY incorporated with each fluorotyrosine 
variant. Protein was excited at 320 nm. 
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In contrast, the sfGFP-TAG151-FY mutants displayed no significant shifts of the 512 
nm emission peak at all excitation wavelengths (Figures 2.10-2.12). The decrease in 
fluorescence intensity present in the spectra was potentially due to differences in protein 
concentration, rather than any meaningful trend. However, it could also be hypothesized 
 
Figure 2.9: Emission spectra of GFP-TAG66-FY incorporated with each 
fluorotyrosine variant. Protein was excited at 395 nm. 
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GFP-TAG66-FY Variant Emission Wavelength (nm) 
WT 507.5 
3 FY 511.5 
2,3 FY 505 
3,5 FY 513.5 
2,3,5 FY 503.5 
2,3,6 FY 489.5 
 
Table 2.2: The emission wavelengths of each GFP-TAG66-FY variant at excitation 
395 nm. Similar trends were seen at both excitations of 300 nm and 320 nm. 
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that the excitation at 395 nm is not the ideal excitation wavelength for the deprotonated 
form (475 nm). This could explain why the 450 nm emission peak for the deprotonated 
tyrosine is much lower than that of the 512 nm emission of the protonated tyrosine where 
it is being excited at the maximum excitation (395 nm). In addition the protonated and 
deprotonated fluorophores have different molar extinction coefficients (ε) that can also 
affect these differences in intensity; the protonated 395 nm excitation has ε equal to 
30,000 M
-1
cm
-1
 while the deprotonated 475 nm excitation has ε of 7,000 M-1cm-1.17 The 
lack of emission peak shifts in the sfGFP-TAG151-FY mutants as compared to the GFP-
TAG66-FY variants could be due to the presence of the fluorotyrosine on the rigid 
outside of β-barrel that does not contribute directly to the fluorophore’s fluorescence.  
 
 
Figure 2.10: Emission spectra of sfGFP-TAG151-FY incorporated with each 
fluorotyrosine variant. Protein was excited at 300 nm. 
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The two peaks present in each spectrum at excitation of 395 nm correlate with the 
protonated (512 nm) and deprotonated (450 nm) forms of the tyrosine. GFP displays 
specific pH sensitivity (typically around pH 5-6) which can be demonstrated 
 
Figure 2.11: Emission spectra of sfGFP-TAG151-FY incorporated with each 
fluorotyrosine variant. Protein was excited at 320 nm. 
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Figure 2.12: Emission spectra of sfGFP-TAG151-FY incorporated with each 
fluorotyrosine variant. Protein was excited at 395 nm. 
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spectroscopically through a shift in relative intensities of the 512 nm and 450 nm peaks. 
At higher pH’s, the deprotonated form (emission at 450 nm) is favored, while at lower 
pH’s the protonated is favored (emission at 512 nm).19,20 Increasing the number of 
fluorine atoms, which results in a change in pKa, should result in shifted pH sensitivity 
for each GFP-FY variant. To determine the differences in pH sensitivity of each variant, 
aliquots of 1M NaOH or 0.6M HCl were added to the 1:300 dilution of protein in PBS 
buffer to determine the effect that the pH had on the ratio of the two peaks. While 
quantitative measurement of the changes in pH was not accomplished, these results 
demonstrated a shift in the two emission peaks in response to changes in pH.  
While these results demonstrated specific shifts, the exact range of the pH sensitivity 
has not yet been determined. To amend this, samples were given to the Harbron lab 
where the experiments were repeated for each sample with the pH measured after each 
aliquot of acid or base. This research is still ongoing, but has showed promising 
correlation of different pH sensitivity with different sfGFP-TAG151-FY variants.  
 
E. Conclusions 
GFP is a highly utilized biosensor in many biological studies.
17,19
 This study could 
result in an entire new set of GFP variants that could be used in more physiological 
conditions through shifting the pH sensitivity of GFP. These GFP variants would 
essentially become pH sensors to potentially detect changes in cellular pH. Two main 
applications of GFP-FY variants appear to be directly apparent for future studies. The 
first utilizes the differences in pKa’s of each variant that are in a more physiological 
range. To determine changes in acidity of cells (such as cancer cells), the ratio of the two 
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fluorescence peaks (450 nm/ 512 nm) or the presence/absence of the 450 nm peak could 
be used to determine acidic conditions. A second method could utilize the shifts in 
emission wavelengths of the GFP-TAG66-FY variants to present a set of fluorescent 
probes that have the same excitation wavelength, but different emissions that could be 
used in a variety of studies. Overall this study offers an expanded selection of fluorescent 
probes to choose from for biological studies.  
While research is still ongoing, preliminary results have returned evidence of distinct 
ranges of pH sensitivity for each GFP-FY variant. GFP-TAG66-FY variants contain 
unique emission spectra as compared to GFP-WT, while sfGFP-TAG151-FY variants 
present unique shifts in pH sensitivity. It appears surprising that the sfGFP-TAG151-FY 
variants respond more readily to pH changes than the GFP-TAG66-FY variants, 
especially considering that Y151 is on the rigid external β-barrel where shifts in tyrosine 
pKa should have a limited effect. It is hypothesized that the protonation state of the 
external β-barrel results in a conformational change to alter the environment of the 
internal fluorophore. However, additional research needs to be done to confirm this 
hypothesis.  
Future studies also involve optimizing the fluorescence spectra peaks by calculating 
for the differences in molar absorptivity and absorption maxima of the two protonation 
forms. Because the deprotonated form’s absorbance maximum is at 475 nm, excitation at 
395 nm may not be detecting the full shifts in intensity between the two peaks. 
Measurement of the fluorescence spectra at excitation 475 nm could result in a more 
optimized fluorescence spectrum of the deprotonated tyrosine form. Moreover, a more in 
depth exploration of the pH sensitivity of both sfGFP-TAG151-FY and GFP-TAG66-FY 
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variants is needed. Eventual future studies will also explore the use of these fluorescent 
probes in a biological setting to demonstrate their practical applications. 
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III. Caging of PRMT1 (Protein Arginine Methyltransferase 1) 
A. Introduction to PRMT1 
A.1 Arginine Methylation 
Post-translational modifications allow an expansion of the chemical capabilities of 
proteins. Due to the additional properties of the appended group (electronegativity, 
hydrophobicity, steric hindrance, removal of hydrogen-binding etc.) these post-
translational modifications can result in conformational changes of the protein, which can 
alter protein function.  The two most common modifications are phosphorylation—the 
addition of a phosphate group to a protein—and methylation—the addition of a methyl 
group. Both modifications are important in the regulation of protein activity and signal 
transduction pathways. Arginine methylation has a number of physiological roles 
including signal transduction, mRNA splicing, transcriptional control, DNA repair, and 
protein translocation.
28
  
Methylation is also important in the regulation of genes through the modification of 
histones that control the expression of DNA.
1
 The DNA strands wrap around histones to 
form nucleosomes such that the DNA strand and histones resemble beads on a string 
(Figure 3.1). Where the histone binds the DNA more tightly, the DNA is unable to be 
transcribed. The tightness of binding is controlled through methylation, in which a 
methylated histone tail binds more tightly.  
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A.2 PRMT Mechanism 
A particular enzyme involved in methylations is Protein Arginine Methyltransferase 
(PRMT), which transfers a methyl group from a methyl donor, S-Adenosyl methionine 
(AdoMet), to an arginine residue on the acceptor protein (Figure 3.2). Due to the 
chemical structure of arginine, methyltransferases can attach one or two methyl groups to 
the terminal guanidine nitrogen of arginine in a symmetric or asymmetric manner (Figure 
3.3). There is no known enzyme that can catalyze both asymmetric and symmetric 
methylation.
28
 As arginine’s guanidine group contains five potential hydrogen bond 
donors, each methylation results in a removal of a hydrogen bond donor that alters the 
protein’s shape, function, and binding interactions.28  
 
Figure 3.1: DNA wraps around an octamer of histones (two copies of H2A, H2B, H3 
and H4) to compose a nucleosome. Histone H1 binds to the DNA in between two 
nucleosomes. The nucleosomes compose the basic units of chromatin.44 
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Methyltransferases that utilize AdoMet as the methyl donator have been classified 
into three categories based on structure and function.
29
 The largest is class I that contain 
the methyltransferases with a common β-sheet structure to methylate DNA, RNA and 
proteins (this class includes PRMT).
29
 Class II  contain the SET lysine methyltransferases 
with a common SET domain that modulate gene activity; and Class III are the 
methyltransferases that associate with the membrane.
29
 Of eleven members of the 
mammalian PRMT family, there are eight in humans that contain known enzymatic 
activity and are broken into two types based on their catalysis: Type I catalyze 
asymmetric methylation of arginine (including PRMT1,-2, -3, -4, -6 and -8) while Type 
II catalyze the symmetric methylation (including PRMT5, -7, -9 and the F-box 
proteins).
29
 The only Type II PRMT that has been identified with certainty in humans is 
PRMT5.
30
 Additionally the activity of PRMT2, -7, and -9 still remains to be elucidated.
28
 
 
Figure 3.2: Protein methyltransferases (PMTs) can either methylate a lysine (PKMT) or 
arginine (PRMT) residue. Both PMTs utilize S-Adenosylmethionine (SAM) as the 
methyl donor. Inhibitors of this catalysis include the byproduct S-Adenisylhomocysteine 
(SAH).31 
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All of these PRMTs are extremely conserved among eukaryotes, especially in the 310 
amino acid catalytic domain.
29
  
 
The activity and specificity of PRMTs remains to be largely unexplored, although it 
appears that over 85% of all PRMT activity is due to PRMT1.
29
 PRMT1 is active as a 
homodimer (MW ~80 kDa) although studies indicate that other oligomers do form in the 
cell (Figure 3.4).
28
 PRMT1 does not recognize specific proteins, rather it recognizes local 
amino acid sequences (including glycine and arginine rich motifs).
29
 One of these 
common methylation sites for PRMT1 is histones, specifically histone 4 at arginine 3 
(H4R3).
29
 Methylation of H4R3 by PRMT1 has been linked to transcriptional activation, 
 
Figure 3.3: The terminal guanidine group of arginine can be methylated in three 
different ways by PRMTs.29  
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while methylation of the same site by PRMT5 (that methylate arginine symmetrically 
rather than asymmetrically) results in transcriptional repression.
31
 According to the 
crystal structure of PRMT1, there are a number of different possible binding sites 
suggesting the versatility of its methylation capacity.
30
 Other PRMT1 substrates include 
transcription factors such as STAT1, RUNX1 and FOXO1.
31
 
 
PRMT1 has a high affinity for its substrate (Km in the low/sub micromolar range), but 
a relatively slow rate (a kcat of 1/min for a decent substrate).
30
 The current proposed 
catalytic mechanism involves two glutamate residues of PRMT1 on the AdoMet binding 
domain that induce an electron redistribution through contact with the guanidino group of 
the arginine to be methylated which permits the attack of a nitrogen on the methyl group 
of AdoMet.
30
 A current debate on the order of AdoMet and peptide binding has supported 
 
Figure 3.4: A representation of the structure of the PRMT1 dimer with bound SAH (in 
orange) and substrate arginine (in black). The SAH binding domain is colored green. 
(PDB 1OR8).30 
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the idea of a random distribution in which each methyl transfer in a demethylation is a 
separate event.
30
 Kinetics studies have demonstrated that the methylation of H4R3 is a 
multiple-step process that includes 1) an ultra-fast binding of substrate (H4), 2) a 
moderately fast formation of the PRMT1-AdoMet-H4 complex, 3) and the rate-limiting 
methylation.
31
 
A.3 PRMT1 in the Human Body 
Arginine methylation by PRMT is not a static post-translation modification, but is a 
rapid modification of protein function.
29
 This contributes to the ever changing activity 
inside the cell, and as a result, PRMT is critical to proper cell and organism growth. Mice 
that contain a complete loss-of-function of PRMT1 are embryonic lethal, suggesting the 
crucial role PRMT1 places in proper signal transduction and organismal survival.
29
 
Moreover, PRMT has been suggested to play a role in insulin signaling and glucose 
metabolism.
28
 Currently, there is still a tremendous amount that remains unknown about 
the specificity, mechanism, and regulation of these enzymes.
28
 However, improper 
regulation of PRMT1 has been linked to cancer, cardiovascular disease, oculopharyngeal 
muscular dystrophy amyotrophic lateral sclerosis (ALS), and several other diseases.
29
 
While many of the mechanisms remain to be elucidated, the relation of PRMT1 to 
cardiovascular disease has been suggested to be through the in vivo inhibition of nitric 
oxide synthase (NOS) as nitric oxide functions as a potent vasodilator.
28
  Proteolysis of 
dimethylated protein can produce the metabolite asymmetrically dimethlated arginine 
(ADMA) which is a competitive inhibitor of NOS, thus inhibition of this enzyme can 
have major consequences on the cardiovascular system and could also result in diabetes 
mellitus, kidney failure, and chronic pulmonary diseases.
29
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Due to this importance in PRMT1 function and regulation, there is a large effort to 
develop inhibitors to be able to study the function and targets of PRMT1 and to combat 
these diseases due to PRMT1 disregulation. The first inhibitor of PRMT1 was identified 
in 1978 that was an analog of AdoMet called sinefungin (Figure 3.5).
29
 Currently there 
are two classes of selective PRMT1 inhibitors: peptide derivatives (mostly used to study 
PRMT1 rather than drug candidates) and organic small molecules.
32
 The small organic 
molecules are difficult to predict, so virtual screens of up to 300,000 compounds have 
been used to yield a few compounds that have promising inhibition of PRMT1.
33
 
However, due to the importance of PRMT1 function, most inhibitors seek to reduce 
PRMT1 activity back to normal levels rather than complete inhibition.
29
 The most 
promising current inhibitors seek to specifically target the PRMT1 substrate rather than 
the enzyme itself to provide targeted inhibition of the specific system.
33
 
 
 
B. UAA: ONBY 
Protein function can be controlled utilizing light-removable protecting groups called 
“caging-groups.” These protecting groups typically contain a nitrobenzyl moiety and are 
installed on amino acids side chains or organic small molecules in such a way that the 
 
Figure 3.5: The structure of the first identified inhibitor of PRMT1, sinefungin, an 
analog of AdoMet. 
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native function of the protein is altered (Figure 3.6).
34
 Irradiation with light (usually UV) 
results in the photolytic cleavage of the caging-group so that the original biomolecule is 
restored. Caging groups have been used in a variety of studies to determine protein 
function and mechanisms through the directed spatiotemporal control of activity.
34
 
Caging groups have been used to study gene expression regulation by small molecules 
effectors such as a caged toyocamycin, a natural antibiotic that inhibits ribozyme 
function.
35
  Protein activity can also be controlled through incorporation of caged amino 
acids into the protein. Traditional methods utilize non-specific reaction of surface lysines 
with a photolabile reagent. However, this method is tedious and inefficient as it involves 
purification of the protein of interest, non-specific caging of surface lysines, 
reintroduction of the caged protein into the biological system, and the caging of important 
residues for activity is not even guaranteed.
34
 The site-specific incorporation of caged 
UAA’s proffers a solution to target specific amino acids critical to protein function.  
 
This study offers a novel mechanism to spatially and temporally control PRMT1 
activity, without the use of external inhibitors. UAAs allow the control of PRMT1 
through the targeted incorporation of caged amino acids that can permit the control of 
PRMT1 function. A caged-tyrosine group can be prepared through the reaction of o-
 
Figure 3.6: The decaging reaction in which UV light catalyzes the photocleavage of 
the caging group (seen here as the ortho-nitrobenzyl group moiety). 
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nitrobenzyl bromide with the amino acid tyrosine. This o-nitrobenzyl-tyrosine (ONBY) 
confers photo-reactivity, providing ultimate spatial and temporal control over protein 
function. Brief irradiation with UV light results in the cleavage of the nitrobenzyl group 
to afford the original tyrosine structure. While the nitroso-aldehyde produced is 
cytotoxic, it would be at such low levels to have limited effect. Light provides a unique 
activation of cleavage as it can be easily localized to the target, and the timing and 
amplitude can be easily regulated.
34
 In addition, light does not involve the use of 
additional reagents like acids or bases that are often used in cleavage procedures. 
 For many proteins, the hydroxyl moiety of tyrosine is key to function, thus the 
caging blocks the hydroxyl from participating in its normal function. This control of 
protein function has been demonstrated in GFP. If the ONBY group is incorporated at 
Tyr66 of GFP, then the fluorescence is quenched. Only after light irradiation does the 
cage-group remove and fluorescence is restored (Figure 3.7).
16
 This method has also been 
used in the regulation of Cre recombinase in which Y324 hydroxyl group is essential for 
catalysis.
35
 Human embryonic kidney cells were transfected with the caged Cre 
recombinase to demonstrate more than 70% catalytic activity recovery after UV 
irradiation to cleave the cage group. 
35,36
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Figure 3.7:  Incorporation of GFP with ortho-nitrobenzyl-tyrosine (ONBY) permits 
recovery of fluorescence after the photo-induced removal of the o-nitrobenzyl moiety. 
(A) Scheme of the decaging of ONBY in GFP fluorophore. (B) Demonstration of GFP 
fluorescence with ONBY incorporation at position Y66 and Y151. GFP with ONBY 
incorporation at Y66 recover fluorescence after only 4 min of 395 nm irradiation while 
Y151 fluorescence is unaffected as the fluorophore is unaffected. GFP without ONBY 
incorporation (-) are nonfunctional and exhibit no fluorescence.16  
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A similar mechanism is proposed for PRMT1 control. The tyrosine at position 291 
has been shown to be important for protein activity as phosphorylation at this site 
removes enzymatic activity.
37
 It was hypothesized that the site-specific incorporation of 
ONBY at Y291 would also result in regulated control over PRMT1 activity. 
 
C. Methods 
General 
Solvents and reagents were obtained from either Sigma-Aldrich or Fisher Scientific and 
used without further purification. All PRMT1 proteins were purified according to 
manufacturer’s protocols using a Qiagen Ni-NTA Quik Spin Kit. Enzyme activity was 
measured with a 265 nm SAM methyltransferase assay by GBiosciences. Absorbance 
was measured at 265 nm on a BioTek Syntergy HT microplate reader on Greiner Bio-
One UV 96-well plates. Human recombinant Histone H4 was obtained from New 
England Biolabs. 
Expression of PRMT1-ONBY 
Escherichia coli BL21(DE3) cells were co-transformed with a pET-PRMT1-TAG-291 
plasmid (0.5 μL) and pEVOL-ONBY plasmid (0.5 μL) using an Eppendorf 
electroporator. Cells were then plated on LB-agar plates supplemented with kanamycin 
(10 mg/mL) and chloramphenicol (34 mg/mL) and grown at 37°C. After 16 h, a single 
colony was selected and used to inoculate LB media (4 mL) supplemented with 
kanamycin and chloramphenicol. The culture was grown at 37°C for 12 h. The culture 
was used to begin an expression culture of LB media (100 mL) at OD600 0.1, then 
incubated at 37°C, to an OD600 of ~0.6, at which point cells were induced with 1 M IPTG 
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(100 μL), 20% arabinose (100 μL) and 100 mM (1000 μL) of o-nitrobenzyl-tyrosine 
(ONBY). Cultures were grown for an additional 48 h at 25°C, then harvested by 
centrifugation (10 min at 10,000 rpm). The media was decanted and the cell pellet placed 
in the -80°C freezer for at 20 min. Purification was accomplished using commercially 
available Ni-NTA spin columns and according to manufacturer’s protocol. Protein yield 
and purity was assessed by SDS-PAGE, and spectrophotometrically using a Nanodrop 
spectrophotometer. 
Synthesis of ONBY 
ONBY was synthesized according to previously described methods by Jackie McKenna.  
O-nitrobenzyl-bromide (61 mg, 1.5 eq, 0.513 mmol) was added to a suspension of cesium 
carbonate (220 mg, 2 eq, 0.677 mmol), Boc-Tyrosine-OMe (100 mg, 1 eq, 0.339 mmol), 
and dimethylformamide (10 mL). The reaction vial was covered with aluminum foil and 
stirred for 20 hours at room temperature. The reaction was extracted with 
dichloromethane and brine. The organic layers were dried over MgSO4 and concentrated. 
Column chromatography (silica gel, 3:1 hexanes/ethyl acetate) afforded the desired 
product (57 mg, 0.132 mmol, 39%). 
To deprotect the unnatural amino acid, 500 μL 1M dioxane and 500 μL 1M lithium 
hydroxide were added to the reaction vial on ice. The vial was covered in aluminum foil 
and stirred at room temperature for 2 hours. The dioxane was evaporated and 6M 
hydrochloric acid was added dropwise until a pH of 4 was achieved. The product was 
extracted with ethyl acetate in a vial, and the organic extracted was dried with MgSO4 
and concentrated. 1 mL of 50% trifluoroacetic acid in DCM was added to the vial on ice 
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and stirred for 1 hour at room temperature. The DCM was evaporated to afford the 
desired product (31 mg, 0.098 mmol, 74%).  
PRMT1 Assay 
A commercially available methyltransferase assay by GBiosciences was used to 
determine the relative activity of the PRMT1 mutants and wild type. A BioTek Synergy 
HT microplate reader was used to measure the absorbance at 265 nm. Readings were 
taken every minute for an hour. Either before or after initial reading, the plate was 
irradiated at 365 nm for 10 min to decage the ONBY group. Absorbance rates were 
converted to enzyme activity following the manufacture’s protocol. This was done by 
finding the slope of the change in absorbance of adenine (a product of the enzymatic 
reaction provided in the kit), and subtracting the slope of the negative control. Beer-
Lambert law and adenine’s molar absorptivity was then used to convert changes in 
absorption to changes in molarity.  
PRMT1 protein samples were prepared by concentrating in PBS using Corning Spin-X 
UF 500 concentrator columns to a concentration of ~0.400 mg/mL. Samples were made 
in triplicate. Substrate for PRMT1 methylation was human recombinant histone 4 (1 
mg/ML) from New England Biolabs. Negative controls were made by excluding histidine 
or PRMT1 protein. Positive control was provided by manufactures and diluted (1:10) in 
provided buffer (5 μL of positive control in 45 μL of assay buffer). 14 μL of PRMT1 WT 
or ONBY protein was added to each well (or 14 μL of buffer for the negative control). 
The histone4 substrate (1 μL) was then added to give a total volume of 15 μL/ well. 5 μL 
of the diluted positive control was diluted again with 10 μL of buffer in the well. 
Following sample preparation, the enzyme master mix (supplied in the assay kit) was 
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prepared by adding 3300 μL of buffer, 100 μL SAM (lyophilized SAM dissolved in 
20mM HCl) and 200 μL of the kit’s enzyme mix. Immediately before the start of the 
assay, 100 μL of the master mix was added to each well and the plate was placed in the 
plate reader to immediately begin measuring absorbance.  
Absorbance measurements were taken every minute for an hour at 37ºC. After an hour, 
the plate was irradiated with UV light (365 nm) for 10 min to decage ONBY. Absorbance 
measurements were then taken for an additional 20 min for every minute. A second trial 
was then run in which samples were irradiated at 365 nm for 10 min before the addition 
of the enzyme master mix. The absorbance was then measured for an hour as before. 
PRMT1 activity was then calculated from the changes in absorbance as described above. 
This assay was completed five times to verify results.  
 
D. Results  
As demonstrated by previous studies of PRMT1, interference of the hydroxyl group 
of Y291 should limit PRMT1 activity.
37
 Consequently caging the hydroxyl group of 
Y291 as ONBY should eliminate all PRMT1 activity when incorporated at Y291. A 
commercial SAM methyltransferase assay by GBiosciences was utilized to determine the 
effect of the UAA insertion on PRMT1 activity. The PRMT1 protein (pET-PRMT1-
TAG291) was expressed for two days at room temperature in E. coli with an orthogonal 
aaRS (pEVOL-ONBY) to permit incorporation of ONBY at Y291. Protein was purified 
to a concentration of about 0.400 mg/mL for analysis of activity. Each trial of the SAM 
methyltransferase assay was run in triplicate, with ONBY decaging occurring both before 
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and after an hour assay run-time. For each trial ONBY was decaged through irradiation 
with UV light (365 nm) for 10 min. 
The assay measures the change in absorption at 265 nm, the absorption wavelength of 
a product, adenine, to correlate with SAM methyltransferase activity. As described in the 
assay scheme, PRMT1 utilizes S-Adenosylmethionine (AdoMet/SAM) as a methyl donor 
to transfer a methyl group to Histone 4 (Figure 3.8). Due to PRMT1’s slow enzymatic 
turnover, the assay measures the reaction product formation rather than reactant 
depletions. In this case, enzymes provided in the kit catalyzed the conversion from the 
demethylated S-Adenosylhomocysteine (SAH) into S-Ribosylhomocysteine and adenine 
which removes the feedback inhibition of SAH on PRMT1. Another enzyme catalyzed 
the deaminiation of adenine into hypoxanthine, which is observed by a decrease in 
absorption. Because these last two enzymatic reactions are so rapid, the measurement of 
the change in absorption of adenine provides an indirect measure of PRMT1 activity. 
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The calculation to convert the absorbance measurement of adenine over the time of 
the assay to the activity of PRMT1 is relatively simple. The absorbance that the plate 
reader gives is in milliOD at each time point. For each of the three sample trials, the 
absorbance at 265 nm was graphed over time and the slope was found using the best fit 
line. The average slope the three trials was taken, and normalized by subtracting the slope 
of the negative control (no substrate added). The rate, currently in milliOD/min, can be 
converted to A/min by simply dividing by 1000. Using the Beer-Lambert law where 
 
Figure 3.8: The general process of the G-Biosciences SAM 265 nm Methyltransferase 
Assay. Nu represents the methyltransferase substrate (in this case H4R3). Additional 
enzymes such as AdoHcy Nucleosidase and Adenine Deaminase were provided in the 
enzyme mix of the assay kit.  The rapid conversion done by these enzymes aids in 
alleviating the feedback inhibition of SAH on PRMT1. PRMT1 activity is measured by 
the change in absorbance at 265 nm resulting from the conversion of adenine to 
hypoxanthine.  
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A=εbc, the rate can be converted to M/min. The extinction coefficient (ε) for adenine is 
13.4 mM
-1
cm
-1
 and the pathlength (b) of the solution in the well is 0.577cm. As the 
protein sample was diluted by the addition of reagents, the dilution factor of 
(0.115mL/0.014mL) must be multiplied to get the final activity of PRMT1 in mM/min. 
To obtain the specific activity of PRMT1, the activity can be divided by the concentration 
of the protein sample. This data analysis was performed for all trials.  
Five full trials of the assay were run, to ensure that the results seen were evident of 
the PRMT1 activity observed. Initial trials were invalid due to the failure to use a 96-well 
plate that could be used in the UV range. Preliminary results appeared promising as there 
was a significant difference in PRMT1-ONBY activity before and after UV irradiation 
(Figure 3.9).  
However, attempts to repeat this experiment with fresh protein did not proceed as 
planned. A lag time between protein expression and the assay resulted in ONBY 
decaging before the experiment (Figure 3.10). While disappointing, this trial 
demonstrated the importance of properly protecting the PRMT1-ONBY protein in 
aluminum foil during storage as light over the course of a month may be sufficient to 
decage the ONBY.  
Additional trials of the assay produced similar results to the first experiment. 
However, it was noted that the negative controls (those lacking either his4 or PRMT1-
WT) had absorbance slopes similar to the positive samples. While it is still not yet 
understood what this means, we are attempting alternative data analysis methods and will 
repeat the experiment again to verify results.  
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Figure 3.9: PRMT1 activity from SAM methyltransferase assay. UV irradiation results 
in the photocleavage of the ONBY to permit PRMT1 methyltransferase activity. 
PRMT1-TAG291-ONBY activity was measured pre-irradiation (PRMT1 caged) and 
post-irradiation (PRMT1 decaged). Error bars indicate standard deviation between the 
triplicate samples.  
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E. Conclusions 
Caging of proteins provides precise spatial and temporal control over protein activity. 
The use of UAAs presents a more site-specific method than that of the previously utilized 
global incorporation, in which the targeting of precise sites like the active site is random 
and uncontrollable. These methods are indispensable in the determination of a protein’s 
characterization. Despite the importance of PRMT1 in the human body, it has yet to be 
fully characterized. This study presents a method to allow a greater determination of 
PRMT1’s function through the spatial and temporal control of its enzymatic activity.  
This study demonstrated that PRMT1’s activity can be controlled through the site-
specific incorporation of ONBY to Y291. The fully caged PRMT1 demonstrated limited 
 
Figure 3.10: PRMT1 Activity from SAM Methyltransferase Assay. After a month in 
the refrigerator, the PRMT1-ONBY was decaged as seen by the similar activity to 
PRMT1-WT both before and after decaging. Error bars indicate standard deviation 
between the triplicate samples.  
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activity in the methyltransferase assay, but its activity was recovered after the decaging of 
ONBY. Other caging groups could also be explored to regulate PRMT1 activity, to be 
able to better elucidate the mechanisms of this misunderstood enzyme. ONBY caging, 
while providing complete inactivation followed by complete activation after 
photocleavage, is irreversible. A reversible mechanism could be utilized to both turn on 
and turn off PRMT1 activity. The fusion of LOV domain, commonly found in plant 
phototropin proteins, to PRMT1 would allow reversible photochemical switching of 
protein activity 
34
. In this system, when the LOV domain is irradiated with blue light 
(450-470 nm), it triggers a confirmation; change in the attached protein. Once the 
irradiation ceases, the protein slowly assumes its original confirmation. However, this 
method may be difficult to predict the optimum LOV fusion site of PRMT1 to allow 
photoswitching of activity.  
Once this technique has been fully optimized, it would be interesting to incorporate it 
into a model organism to better determine the activity of PRMT1. Just as PRMT1’s 
activity was controlled in vitro, an in vivo assay would prove useful to spatially or 
temporally control the enzyme’s activity to determine its function at specific areas of the 
body or time of life.    
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IV. Glaser-Hay Bioconjugation 
A. Introduction to Bioconjugates 
A.1 Bioconjugates and Their Uses 
Bioconjugation, in the simplest definition, is the attachment of two molecules 
(one typically biological in nature) through a covalent bond (Figure 4.1).
38
 As a synthetic 
technique, both the molecules and the coupling mechanism can be directly chosen for the 
specific application. While dozens of chemical reactions are available, less than ten 
different reactions are typically utilized to create bioconjugates due to several key 
requirements for their preparation including the mild reaction conditions to produce of a 
physiologically stable linkage.
38
 However, these same coupling reactions have been 
successfully utilized to create a diverse range of bioconjugates for further use, 
demonstrating the versatility of the bioconjugation methods. Primary uses of 
bioconjugates include fluorescent/biological probes to study protein activity in normal 
and diseased systems and development of therapeutic techniques such as anti-bodies as 
drug delivery systems.
38–40
 
 
For study of biological systems, the coupling reactions that are utilized typically 
must be biorthogonal (although the coupling could also occur outside of the system). 
These biorthogonal reactions are chemical reactions that are able to proceed in a 
 
Figure 4.1: The basic process of conjugation. For bioconjugations, one of the 
conjugates would be biological in nature.  
+
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biological system without perturbing or reacting with any of the endogenous components 
of the cell or system, and rely on chemical functionalities that are not normally present in 
the biological system.
39
 These reactions must meet several requirements to be useful in 
the generation of bioconjugates including biologically compatible and mild reaction 
conditions, production of a physiologically stable linkage, and a degree of 
chemoselectivity.
38
 So far, a number of biorthogonal reactions have been utilized in 
developing diagnostics and therapeutics including Staudinger ligation, Huisgen 1,3-
dipolar Cycloaddition (click) reaction, tetrazine ligation, oxime formations, and 
photocrosslinking reaction.
39
 One of the most commonly used reactions is the click 
reaction involving an alkyne and azide to yield a highly stable triazole linker (Scheme 
4.1). A wide range of alternative reactions have developed from this including those in 
the absence of catalysts to increase its biocompatibility.
38
 However, additional 
development of novel methodologies will permit extended versatility and maximized 
applications for bioconjugates. 
 
A.2 Glaser-Hay Biorthogonal Reaction 
 Despite the number of biorthogonal reactions available, additional reactions 
should be assessed for further use and study. This study proposes the utilization of the 
Glaser-Hay coupling of terminal alkynes as a novel biochemical conjugation strategy.  
The Glaser-Hay reaction provides the coupling of two terminal alkynes under a 
copper-iodine/TMEDA catalyst system (Scheme 4.2). This reaction affords an ideal 
 
Scheme 4.1:  1,3 dipolar cycloadditions (“Click” Reaction)  
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conjugation strategy through its formation of a highly stable and rigid carbon-carbon 
bond that can be formed under mild conditions and without a potentially photosensitive 
azide. Additionally, the reagents/catalysts are cost efficient and numerous alkyne linkers 
and conjugation partners are commercially available. The product formed is a highly 
oxidized linear diyne that is capable of numerous additional reactions.  Moreover, this 
reaction tolerates a wide range of functional groups, which makes it applicable in the 
development of therapeutics. 
 
B. UAA: Alkyne Handle of Propargyloxyphenylalanine 
Despite the usefulness of bioconjugates, they are severely limited through the lack of 
control in the number and location of conjugation sites. Typical methods utilize the 
available lysine and cysteine residues present in the protein conjugates. However, this 
method does not offer site-specific control over the location of the bioconjugates linkage 
due to the high amount of lysine and cysteine residues present in proteins. The utilization 
of biorthogonal handles through UAA incorporation proffers an efficient method to 
incorporate site-specific control over the conjugation reaction. UAAs can be developed 
that contain terminal alkyne functionalities that can be site-specifically incorporated into 
the protein of interest. The length of the handle can also be modified to extend the reach 
of the bioconjugation reaction to allow for optimum Glaser-Hay reaction conditions. For 
GFP, residue Y151 was an ideal site to incorporate a biorthogonal alkyne handle as 
 
Scheme 4.2: The Glaser-Hay Reaction in which a copper/base catalyst system is 
utilized to produce a linear diyne product.  
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position 151 is on a surface exposed portion of the rigid β-barrel and does not impact 
GFP fluorescence. 
The alkyne handle utilized in this study was propargyloxyphenylalanine due to its 
previously described synthesis and availability of a previously evolved aaRS (pEVOL-
pPrF) to incorporate it into protein (Figure 4.2).
41
 
 
C. Methods  
General 
Solvents and reagents, including the AlexaFluor 488 Alkyne, were obtained from either 
Sigma-Aldrich or Fisher Scientific and used without further purification. Epoxy-activated 
Sepharose 6B was obtained from GE Healthcare. Reactions were conducted under 
ambient atmosphere with solvents directly from the manufacturer. All GFP proteins were 
purified according to manufacturer’s protocols using a Qiagen Ni-NTA Quik Spin Kit. 
Samples were analyzed on an Agilent 6520 Accurate-Mass Quadrupole-Time-of-Flight 
(Q-TOF) mass spectrometer equipped with an electrospray (ESI) ionization source and 
liquid chromatography (LC) (Agilent).  Ionization settings were: positive mode; capillary 
voltage 3500 kV; fragmentor voltage 200 V; drying gas temperature 350 °C.  Instrument 
was set to standard 2 GHz, extended dynamic range and deconvolution was performed by 
 
Figure 4.2: The alkyne handle UAA, propargymoxyphenylalanine, utilized in 
Glaser-Hay bioconjugations 
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Agilent MassHunter Qualitative Analysis software using the maximum entropy 
setting.  To separate analyte a 2.1x150 mm, C8 reverse phase, wide pore (5 μm, 300 Å, 
Phenomenex) column was used with a water (A)/acetonitrile (B) (0.1% formic acid) 
gradient (2% B for 3 min, followed by a 2-95% B gradient over 15 min, and 95% B for 7 
min). 
Glaser-Hay Aqueous Conditions 
Aqueous conditions for the Glaser-Hay reaction were optimized by preparing a 
phenylacetlyene homodimer. To a vial containing H2O (3 mL) was added TMEDA (10 
μL, 0.06 mmol) and CuI (10 mg, 0.05 mmol), forming the catalyst complex. 
Phenylacetylene (37 mg, 0.364 mmol) was then added and the reaction was allowed to 
stir at room temperature for 16 h. The reaction was extracted using EtOAc and H2O 
washes (4 x 5 mL ea.), concentrated and dried in vacuo. The product was obtained as a 
white solid: 88 mg, 0.349mmol, 96% yield; 
1
H NMR (400 MHz; CDCl3): ∂ 7.38-7.56 (m, 
J = 7.2 Hz, 10H). 
Expression of GFP-pPrF-151 
Escherichia coli BL21(DE3) cells were co-transformed with a pET-GFP-TAG-151 
plasmid (0.5 μL) and pEVOL-pPrF plasmid (0.5 μL) using an Eppendorf electroporator. 
Cells were then plated on LB-agar plates supplemented with ampicillin (50 mg/mL) and 
chloramphenicol (34 mg/mL) and grown at 37°C. After 16 h, a single colony was 
selected and used to inoculate LB media (4 mL) supplemented with ampicillin and 
chloramphenicol. The culture was grown at 37°C for 12 h. The culture was used to begin 
an expression culture of LB media (10 mL) at OD600 0.1, then incubated at 37°C, to an 
OD600 of ~0.6, at which point cells were induced with 1 M IPTG (10 μL), 20% arabinose 
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(10 μL) and 100 mM pPrF (100 μL). Cultures were grown for an additional 16 h at 37°C, 
then harvested by centrifugation (10 min at 10,000 rpm). The media was decanted and the 
cell pellet placed in the -80°C freezer for at 20 min. Purification was accomplished using 
commercially available Ni-NTA spin columns and according to manufacturer’s protocol. 
Protein yield and purity was assessed by SDS-PAGE, LC/MS, and 
spectrophotometrically using a Nanodrop spectrophotometer. 
Protein-Fluorophore Glaser Hay Bioconjugation 
The expressed GFP-pPrF-151 was coupled to AlexaFluor 488 alkyne using Glaser-Hay 
reaction conditions. In an eppendorf tube, 500 mM CuI (5 μL) and 5uL 500 mM TMEDA 
(5 μL) were mixed and equilibrated at 37°C. After 10 minutes, 1 mM AlexaFluor 488 
alkyne (10 μL) was added and equilibrated at 37°C for 10 min.  Finally, GFP-pPrF-151 
(20 μL, 0.5 mg/mL) was added. A control reaction was also prepared with the same 
concentrations of fluorophore and protein, but with the catalyst system replaced with PBS 
buffer (10 μL). The reactions were incubated for various times at 37 °C. Reactions were 
then purified through centrifugal concentration on Spin-X UF colums (Corning), with 
wash cycles of PBS buffer (5 x 100 μL) until flow-through was free of fluorophore. The 
protein was then analyzed by SDS-PAGE gel to verify coupling of the fluorophore to the 
protein. Timecouse experiments were analyzed by comparing densiometry of fluorescent 
bands to their coomasie stained bands using a Biorad Molecular Imager Gel Doc XR+ 
system. 
Immobilization of Alkynes onto Sepharose Resin 
Epoxy-activated 6B Sepharose (GE Healthcare, 200 mg) was added to a filter syringe and 
washed with dH2O (5 x 3 mL). Alkyn-ol (700 µmol) and coupling buffer (3.5 mL, pH 
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13.0) were added to a 15 mL falcon tube followed by the resin. The mixture was 
incubated at room temperature for 16 h. The resin was then transferred to a filter syringe 
and washed with coupling buffer (5 x 4 mL), and transferred to a 15 mL falcon tube with 
ethanolamine (3.5 mL). The resin was incubated at 30 
o
C for 4 h then washed in a filter 
syringe with 10 mM acetate buffer (pH 4) and Ttris-HCl buffer (pH 8) for  3 cycles (4 
mL ea.)  
Attaching Immobilized resin to Protein 
The expressed GFP-alkyne was then coupled to the immobilized resin using the Glaser-
Hay reaction conditions. To eppendorf tube, 5 μL CuI (500 mM) and 5 μL TMEDA (500 
mM) were combined and equilibrated at 37°C for 10 minutes. To the Eppendorf was 
added 30 mg of immobilized resin and again equilibrated at 37°C.  After an additional 10 
minutes, 20 μL of concentrated GFP-alkyne was added. A control reaction was also set 
up using 30 mg immobilized resin, 20 μL GFP-alkyne, and 10 μL PBS buffer. The 
reactions were allowed to shake at 37°C for six hours, 170rpm. After six hours, reactions 
were washed on filter columns using PBS buffer (200 μL aliquots x 10). The washed 
resin-protein mixture was transferred to an Eppendorf tube and imaged for fluorescence.  
Resin-Fluorophore Glaser Hay Conjugation 
The alkyne derivatized resin was reacted under previously described conditions with the 
AlexaFluor 488. To an eppendorf tube, 500 mM CuI (5 μL) and 500 mM TMEDA (5 μL) 
were mixed and equilibrated at 37 °C for 10 min. Alkyne derivatized Sepharose (30 mg) 
was added and equilibrated at 37 °C.  After an additional 10 minutes, 1 mM AlexaFluor 
488 alkyne (5 μL) was added. A control reaction was also performed using 30 mg 
immobilized resin, AlexaFluor 488 alkyne (5 μL), and 10 μL 100 mM PBS buffer. The 
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reactions were allowed to incubate at 37 °C for 6 h. The reactions were then washed on 
filter columns using 100 mM PBS buffer (10 x 200 μL). The fluorophore derivatized 
resin was transferred to an eppendorf tube and imaged for fluorescence using a BioRad 
Molecular Imager Gel Doc system.  
Protein-Resin Glaser Hay Immobilziation 
The alkyne derivatized resin was reacted under previously described conditions with the 
GFP-pPrF-151 protein. To an eppendorf tube, 500 mM CuI (5 μL) and 500 mM TMEDA 
(5 μL) were mixed and equilibrated at 37 °C for 10 min. Alkyne derivatized Sepharose 
(30 mg) was added and equilibrated at 37 °C.  After an additional 10 minutes, GFP-pPrF-
151 (5 μL, 0.5 mg/mL) was added. . A control reaction was also performed using 30 mg 
immobilized resin, GFP (5 μL), and 10 μL 100 mM PBS buffer. The reactions were 
allowed to incubate at 37 °C for 6 h. The reactions were then washed on filter columns 
using 100 mM PBS buffer (10 x 200 μL). The protein immobilized resin was transferred 
to an eppendorf tube and imaged for fluorescence using a BioRad Molecular Imager Gel 
Doc system.  
 
D. Results  
To assess the feasibility of employing the Glaser-Hay reaction for bioconjugation, the 
reaction needed to be optimized for compatibility in aqueous conditions. Gratifyingly, the 
proof-of-concept reactions utilizing the homodimerization of either phenylacetylene or 
propargyl alcohol proceeded to completion in aqueous solvent after 16 hours at room 
temperature with a CuI/TMEDA catalyst. These conditions were based on previously 
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optimized Glaser-Hay conditions in organic solvents and were able to produce greater 
than 95% yields.
42
 
With the aqueous conditions for the Glaser-Hay reaction determined, the next step 
was to utilize it within the context of a protein. Propargyloxyphenylalanine was chosen as 
the alkynyl UAA to serve as a biorthogonal handle, as both its synthesis and an aaRS that 
recognizes it have been previously developed.
41
 GFP was chosen as the protein for UAA 
incorporation due to its fluorescent properties and well-defined role as a reporter system. 
If the UAA were not correctly site-specifically incorporated into GFP, the nonsense 
codon would result in termination of the protein and GFP fluorescence would be lost. 
Also, the natural fluorescence of GFP allows for easy tracking of protein production and 
conjugation.  
The first experiment to determine the feasibility of bioconjugation utilizing the 
Glaser-Hay reaction was done between the mutant GFP and an AlexaFluor-488 modified 
alkyne. Utilizing the Cu/TMEDA catalyst, the reaction was incubated at either 37°C or 
4°C to determine the optimum temperature of incubation. Following reaction completion, 
the catalyst and excess fluorophore were removed by centrifugation and the solution 
exchanged into PBS. The reactions were analyzed using SDS-PAGE to compare the gel 
under fluorescent imaging and Coomassie blue staining. Because the GFP was denatured 
in the gel, the only fluorescent bands that should be seen are those of the successful 
bioconjugation with the fluorophore.  
Initial trials employed an overnight reaction time; however, it was found that this 
resulted in decreased protein concentrations in the SDS-PAGE gel, suggesting protein 
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degradation. A time course employing slower reaction times was then attempted (from 
0.5 to 12 hrs at 4ºC or 37ºC) to determine the optimum conditions (Figure 4.3-4.4) 
 
 
Figure 4.3: SDS-PAGE analysis of Glaser-Hay bioconjugations of GFP-pPrF-151 and 
the fluorophore. Reaction time varied from 0.5-6 hrs. Gels were first imaged for 
fluorescence, then stained with Coomassie. The densiometry of each band was 
measured to generate a ratio of total protein to fluorescently labeled protein.  
 
Figure 4.4: Glaser-Hay timecourse optimization. The ratio of the intact GFP to 
fluorescence of SDS-PAGE gel bands was taken to give a % coupling. Error bars 
indicate standard deviation between the three trials. Results indicate that the optimum 
conditions are 6 hr at 4°C. Extended reaction times lead to protein degradation.  
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Based on these results, 6 hours at 4°C appear to be the optimum conditions for the 
Glaser-Hay bioconjugation. Extended couplings led to decreased fluorescence and overall 
lower intact GFP upon staining, which could be a result of Cu(I) oxidative degradation of 
the protein over time. Indeed in a trial with a reduction of the concentration of the Cu(I) 
catalyst, there was more intact GFP upon staining. However, this reduced concentration 
in the reaction conditions yielded decreased fluorescent labeling (Figure 4.5).  
 
 
Figure 4.5: SDS-PAGE analysis of Glaser-Hay bioconjugations of GFP-pPrF-151 and 
fluorophore with dilutions of the catalyst system. Dilutions (1:10 or 1:100) were made 
to both the copper and TMEDA.  (A) SDS-PAGE gel analysis after Coomassie Blue 
staining displays the limited protein band in the normal concentrations of catalysts. (B) 
SDS-PAGE gel analysis demonstrates high amount of coupling in lane 2 with no 
dilutions, and very limited coupling in any lanes with dilutions.  
Cu/TMEDA
Concentrations Undiluted 1:10 1:100 --
A
B
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The optimal conditions were utilized to demonstrate the utility of the Glaser-Hay 
bioconjugation. Fluorescent labeling of the protein was observed at both temperatures, 
with 4 °C affording slightly higher fluorescence (Figure 4.6, Lanes 2 and 4). Control 
reactions lacking the Cu/TMEDA catalyst system demonstrated protein presence, but no 
fluorescent labeling (Figure 4.6, Lane 6). This control demonstrates that the fluorescent 
labeling seen with the catalyst system present was due to the Glaser-Hay coupling rather 
than non-covalent interactions of the protein with the fluorophore.  
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To probe the utility of this novel bioconjugation in regards to solid-supported 
reactions, the Glaser-Hay reaction was used to couple the fluorophore and GFP to a solid-
support. A propargyl alcohol derivatized Sepharose 6B resin was reacted under similar 
 
Figure 4.6:  Glaser-Hay bioconjugation reactions for 6 hr. at 37°C and 4°C.  (A) SDS-
PAGE gel analysis after Coomassie Blue staining. Successful incorporation of pPrF 
demonstrated by the presence of the band in lane 6 and not in lane 7.  The bands in 
lanes 2 and 4 demonstrate the presence of the conjugated GFP-pPrF-151 after the 
Glaser-Hay reaction completion.  (B) SDS-PAGE gel analysis indicating successful 
conjugation of protein to fluorophore. Fluorescence of bands in lanes 2 and 4 
demonstrates the successful coupling. Lanes 3 and 5 indicate no attached fluorophore.  
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conditions with the AlexaFluor-488 alkyne. A control was run in the absence of the 
fluorophore and the catalyst system. After several PBS washes, the fluorescence of the 
resin was observed, and only the reactions with both the catalyst and fluorophore resulted 
in visible fluorescence (Figure 4.7). From these results and the previous bioconjugation 
conditions, attempts were made to translate this reaction to the immobilization of GFP to 
a solid-support (Figure 4.8). Utilizing the GFP-pPrF-151 mutant and the optimized 
conditions, GFP was immobilized on both a propargyl alcohol and 1-hexynol resin 
(Figure 4.9). Additional controls lacking with Cu(I)/TMEDA catalyst system presented 
little to no detectable fluorescence, demonstrating that non-covalent interactions between 
protein and resin are not the cause of the increased fluorescence of the reaction with the 
catalyst system. From this it can be concluded that the Glaser-Hay coupling was able to 
successfully immobilize GFP containing an alkyne handle to a solid-support.  
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Figure 4.7: Propargyl alcohol immobilized Sepharose resin reacted with an alkynl 
fluorophore.  Successful Glaser-Hay coupling of the fluorophore to the resin is 
demonstrated by the highly fluorescent resin with the catalyst (right) as compared to 
the resin with absence of catalyst (left) and no Glaser-Hay coupling.  
 
Figure 4.8: GFP with alkynyl UAA insertion at the surface-exposed position 151 
undergoing the envisioned Glaser-Hay reaction to successfully immobilize GFP to a 
solid support. 
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Figure 4.9: Immobilization of GFP to resin using Glaser-Hay coupling. Fluorescence 
is only observed in presence of both GFP and the catalyst system, indicating 
successful Glaser-Hay coupling to both (A) immobilized propargyl alcohol Sepharose 
resin and (B) the hexynol derivatized Sephorose 6B resin. (C) Fluorescence data of 
completed reactions with both propargyl alcohol and hexynol loaded Sepharose resins. 
Controls lacking catalyst system demonstrate low background fluorescence only 
attributed to the resin, while GFP-pPrF-151 reacted with the catalyst and resin indicate 
strong fluorescence. Error bars indicate standard deviations.  
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E. Conclusions  
As discussed previously, bioconjugations have become widely functional in 
biological applications. This research demonstrates the adaptation of the Glaser-Hay 
reaction to an aqueous environment and a novel bioconjugation method to immobilize 
proteins to solid-support utilizing UAA technologies. The formation of the linear carbon-
carbon bond affords a highly stable linkage utilizing mild reaction conditions and 
photochemically inert starting materials. Additionally, this research demonstrates the 
breadth of the applicability of this method through applications in small molecule 
dimerizations, protein-fluorophore conjugations, fluorophore-resin conjugations, and 
protein-resin immobilizations. As seen, this method presents a viable alternative to click 
conjugations and will certainly be widely utilized.
43
 
Future work aims to expand the scope of the conjugations through applications as 
therapeutic agents. Other proteins should be tried to determine the full effect of 
immobilization on enzyme activity and its application. Further experiments manipulating 
the length of the alkyne handle are currently underway to determine its effect on reaction 
conditions. Overall, this novel method of bioconjugation presents a widespread field of 
future developments and uses.  
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V. Conclusions  
The expanded amino acid library gives a host of new protein functionalities that 
would not be possible with just the canonical twenty amino acids. This development 
allows a greater specificity and efficiency in protein production to serve both the health 
and engineering industries. Unnatural amino acids provide an expanded application of 
proteins to use as therapeutics, biosensors, structural determinism, and mechanisms of 
unique chemistry that would otherwise be impossible through previous methods.  
This study has demonstrated the utility of three amino acids in altering fluorescence 
to develop biological probes, spatial and temporal control over protein activity, and as 
linkers for protein immobilization. The site-specific alterations that UAA’s can enact 
upon proteins permits the development of novel biochemical tools for bioimaging, 
enzymatic study, and bioconjugation that would otherwise be difficult to create. Future 
works will certainly embrace the wide range of functionality that UAA incorporation has 
to offer.  
 
  
 
 
72 
 
References 
1. Allison, L. A. Fundamental Molecular Biology. (John Wiley & Sons, Inc., 2012). 
2. Zhang, W. H., Otting, G. & Jackson, C. J. Protein engineering with unnatural 
amino acids. Curr. Opin. Struct. Biol. 23, 581–7 (2013). 
3. Kim, C. H., Axup, J. Y. & Schultz, P. G. Protein conjugation with genetically 
encoded unnatural amino acids. Curr. Opin. Chem. Biol. 17, 412–419 (2013). 
4. Liu, C. C. & Schultz, P. G. Adding new chemistries to the genetic code. Annu. 
Rev. Biochem. 79, 413–444 (2010). 
5. Voloshchuk, N. & Montclare, J. K. Incorporation of Unnatural Amino Acids for 
Synthetic Biology. Mol. Biosyst. 6, 65–80 (2010). 
6. Maurya, I. K. et al. Mechanism of action of novel synthetic dodecapeptides against 
Candida albicans. Biochim. Biophys. Acta 1830, 5193–203 (2013). 
7. Amblard, M., Fehrentz, J. a, Martinez, J. & Subra, G. Methods and Protocols of 
modern solid phase peptide synthesis. Mol. Biotechnol. 33, 239–254 (2006). 
8. Coin, I., Beyermann, M. & Bienert, M. Solid-phase peptide synthesis: from 
standard procedures to the synthesis of difficult sequences. Nat. Protoc. 2, 3247–
3256 (2007). 
9. Hendrickson, T., de Crecy-Lagard, V. & Schimmel, P. Incorporation of non-
natural amino acids into proteins [Review]. Annu. Rev. Biochem. 73, 147–76 
(2004). 
10. Wang, L., Xie, J. & Schultz, P. G. Expanding the genetic code. Annu. Rev. 
Biophys. Biomol. Struct. 35, 225–249 (2006). 
11. Opitz, C. a et al. Damped elastic recoil of the titin spring in myofibrils of human 
myocardium. Proc. Natl. Acad. Sci. U. S. A. 100, 12688–93 (2003). 
12. Wilkins, B. J. et al. Site-specific incorporation of fluorotyrosines into proteins in 
Escherichia coli by photochemical disguise. Biochemistry 49, 1557–9 (2010). 
13. Clancy, S. & Brown, W. Translation: DNA to mRNA to protein. Nat. Educ. 1, 101 
(2008). 
14. Wang, K., Schmied, W. H. & Chin, J. W. Reprogramming the genetic code: from 
triplet to quadruplet codes. Angew. Chem. Int. Ed. Engl. 51, 2288–97 (2012). 
 
 
73 
 
15. Young, D. D. et al. An evolved aminoacyl-tRNA synthetase with atypical 
polysubstrate specificity. Biochemistry 50, 1894–1900 (2011). 
16. Niu, W. & Guo, J. Expanding the chemistry of fluorescent protein biosensors 
through genetic incorporation of unnatural amino acids. Mol. Biosyst. 9, 2961–70 
(2013). 
17. Ward, W. W. in Green Fluorescent Protein: Properties, Applications, and 
Protocols (eds. Chalfie, M. & Kain, S. R.) 39–65 (John Wiley & Sons, Inc., 2006). 
18. Cotton, G. J. & Muir, T. W. Generation of a dual-labeled fluorescence biosensor 
for Crk-II phosphorylation using solid-phase expressed protein ligation. Chem. 
Biol. 7, 253–61 (2000). 
19. Craggs, T. D. Green fluorescent protein: structure, folding and chromophore 
maturation. Chem. Soc. Rev. 38, 2865–75 (2009). 
20. Tsien, R. Y. The Green Fluorescent Protein. Annu. Rev. Biochem. 67, 509–44 
(1998). 
21. Pond, M. P., Wenke, B. B., Preimesberger, M. R., Rice, S. L. & Lecomte, J. T. J. 
3-Fluorotyrosine as a Complementary Probe of Hemoglobin Structure and 
Dynamics : A 19 F-NMR Study of Synechococcus sp . PCC 7002 GlbN. Chem. 
Biodivers. 9, 1703–1717 (2012). 
22. Votchitseva, Y. A., Efremenko, E. N. & Varfolomeyev, S. D. Insertion of an 
unnatural amino acid into the protein structure : preparation and properties of 3 f 
luorotyrosine containing organophosphate hydrolase. Russ. Chem. Bull. 55, 369–
374 (2006). 
23. Ren, X. et al. Kinetic and structural characterization of human manganese 
superoxide dismutase containing 3-fluorotyrosines. J. Mol. Struct. 790, 168–173 
(2006). 
24. Rappaport, F. et al. Probing the coupling between proton and electron transfer in 
photosystem II core complexes containing a 3-fluorotyrosine. J. Am. Chem. Soc. 
131, 4425–33 (2009). 
25. Minnihan, E. C., Young, D. D., Schultz, P. G. & Stubbe, J. Incorporation of 
Fluorotyrosines into Ribonucleotide Reductase Using an Evolved, Polyspecific 
Aminoacyl-tRNA Synthetase. J. Am. Chem. Soc. 133, 15942–15945 (2011). 
26. Seyedsayamdost, M. R., Reece, S. Y., Nocera, D. G. & Stubbe, J. Mono-, di-, tri-, 
and tetra-substituted fluorotyrosines: new probes for enzymes that use tyrosyl 
radicals in catalysis. J. Am. Chem. Soc. 128, 1569–79 (2006). 
 
 
74 
 
27. Pédelacq, J.-D., Cabantous, S., Tran, T., Terwilliger, T. C. & Waldo, G. S. 
Engineering and characterization of a superfolder green fluorescent protein. Nat. 
Biotechnol. 24, 79–88 (2006). 
28. Bedford, M. T. & Clarke, S. G. Protein arginine methylation in mammals: who, 
what, and why. Mol. Cell 33, 1–13 (2009). 
29. Nicholson, T. B., Chen, T. & Richard, S. The physiological and 
pathophysiological role of PRMT1-mediated protein arginine methylation. 
Pharmacol. Res. 60, 466–74 (2009). 
30. Wahle, E. & Moritz, B. Methylation of the nuclear poly(A)-binding protein by 
type I protein arginine methyltransferases - how and why. Biol. Chem. 394, 1029–
43 (2013). 
31. Luo, M. Current chemical biology approaches to interrogate protein 
methyltransferases. ACS Chem. Biol. 7, 443–463 (2012). 
32. Hu, H. et al. Exploration of cyanine compounds as selective inhibitors of protein 
arginine methyltransferases: synthesis and biological evaluation. J. Med. Chem. 
58, 1228–43 (2015). 
33. Wang, J. et al. Pharmacophore-based virtual screening and biological evaluation of 
small molecule inhibitors for protein arginine methylation. J. Med. Chem. 55, 
7978–87 (2012). 
34. Riggsbee, C. W. & Deiters, A. Recent advances in the photochemical control of 
protein function. Trends Biotechnol. 28, 468–475 (2010). 
35. Deiters, A. Light activation as a method of regulating and studying gene 
expression. Curr. Opin. Chem. Biol. 13, 678–686 (2009). 
36. Edwards, W. F., Young, D. D. & Deiters, A. Light-activated Cre recombinase as a 
tool for the spatial and temporal control of gene function in mammalian cells. ACS 
Chem. Biol. 4, 441–445 (2009). 
37. Rust, H. L. et al. Using unnatural amino acid mutagenesis to probe the regulation 
of PRMT1. ACS Chem. Biol. 9, 649–55 (2014). 
38. Hermanson, G. T. Bioconjugate Techniques. (Academic Press, 2013). 
doi:10.1016/B978-0-12-382239-0.00001-7 
39. Zheng, M., Zheng, L., Zhang, P., Li, J. & Zhang, Y. Development of 
bioorthogonal reactions and their applications in bioconjugation. Molecules 20, 
3190–205 (2015). 
 
 
75 
 
40. Sletten, E. M. & Bertozzi, C. R. Bioorthogonal chemistry: Fishing for selectivity in 
a sea of functionality. Angew. Chemie - Int. Ed. 48, 6974–6998 (2009). 
41. Deiters, A. & Schultz, P. G. In vivo incorporation of an alkyne into proteins in 
Escherichia coli. Bioorganic Med. Chem. Lett. 15, 1521–1524 (2005). 
42. Tripp, V. T., Lampkowski, J. S., Tyler, R. & Young, D. D. Development of solid-
supported glaser-hay couplings. ACS Comb. Sci. 16, 164–7 (2014). 
43. Raliski, B. K., Howard, C. A. & Young, D. D. Site-Speci fi c Protein 
Immobilization Using Unnatural Amino Acids. Bioconjug. Chem. 25, 1916–1920 
(2014). 
44. Figueiredo, L. M., Cross, G. A. . & Janzen, C. J. Epigenetic regulation in African 
trypanosomes: a new kid on the block. Nat. Rev. Microbiol. 7, 504–513 (2009).  
 
